Ista, Tanabe Seiyaku deal

Tanabe granted ISTA exclusive rights to develop and commercialize nasal forms of bepotastine in North American to treat allergy symptoms. ISTA expects to initiate clinical trials of the nasal form of the selective histamine H1 receptor antagonist in late 2008. Tanabe will receive $2 million up front and is eligible for milestones and royalties. ISTA also received an option for North American rights to oral forms of bepotastine. ...